What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT04436978

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04436978
  • EudraCT 2022-001298-30
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04436978. Randomized; single masking; primary purpose prevention. Start 2023-01-11 (actual); primary completion 2027-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
Acronym
WOEST-3
Condition
Acute Coronary Syndrome
Condition
STEMI - ST Elevation Myocardial Infarction
Condition
NSTEMI - Non-ST Segment Elevation MI
Condition
Bleeding
Condition
Stroke
Condition
Stent Thrombosis
Condition
Embolism
Intervention (Drug)
30-day DAPT
Intervention (Drug)
Guideline-directed therapy
Lead sponsor
St. Antonius Hospital (class: other)
Collaborator
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct04436978
Content hash
1a3ea5b26c686a46ce65a28e80e75820640345ce567a9342aa2f5992bbdf8e3e